Leuprorelin Drugs Market Size, Trends, and Innovations
The global leuprorelin drugs market was valued at $2.60 billion in 2023 and is expected to grow to $4.78 billion by 2034, with a compound annual growth rate (CAGR) of 5.7% from 2024 to 2034. The increasing demand for leuprorelin drugs is driven by their effectiveness in treating a variety of hormone-related health conditions.
Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5282
Market Overview Leuprorelin, a gonadotropin-releasing hormone (GnRH) agonist, is approved by the FDA for treating several conditions, including endometriosis, breast cancer, paraphilia, hypersexuality, central precocious puberty, and prostate cancer. The growing use of these drugs across such applications is fueling the market’s expansion. The rise in central precocious puberty, particularly among the newer generations, is linked to dietary changes, including hormone-injected foods such as eggs, milk, and poultry. Additionally, there has been a notable increase in transgender surgeries, with leuprorelin playing a key role in hormone treatment for male-to-female transgender individuals.
Leuprorelin Drugs Market Trends In December 2023, Daewoong Pharmaceutical Co. Ltd. and Zydus Lifesciences Ltd. entered into a licensing agreement to jointly develop and market a generic form of leuprolide acetate for depot suspension. This drug is commonly used to treat conditions such as endometriosis, advanced prostate cancer, and uterine fibroids.
In September 2023, Astellas Pharma Inc. announced that the European Medicines Agency (EMA) had approved the Type II version of its XTANDI® (enzalutamide) for hormone-sensitive prostate cancer patients who have not experienced metastasis.
Growing Demand from Gender-Affirming Surgeries The rise in gender-affirming surgeries has significantly impacted the demand for leuprorelin drugs. These drugs are commonly used in hormone therapy, which is a key part of many gender-affirming treatments. Leuprorelin helps suppress the production of testosterone and estrogen, which is essential for these procedures. As the number of people seeking gender-affirming surgeries increases, the demand for leuprorelin drugs is expected to grow as well.
For example, in the U.S., up to 78% of transgender or nonbinary individuals have a gender identity or expression that differs from the sex they were assigned at birth. Between 2019 and 2023, over 13,000 gender reassignment surgeries were performed on individuals aged 17.5 years or younger, with the youngest patient being just seven years old.
Challenges Facing the Leuprorelin Drugs Market Despite its effectiveness, leuprorelin medications are associated with several side effects that could discourage some individuals from using them. These include potential exacerbation or onset of metabolic conditions such as diabetes, hyperglycemia (high blood sugar), hyperlipidemia, cirrhosis, or non-alcoholic fatty liver disease.
Recent Developments
- In November 2022, Leuprolide Acetate Injection Depot 22.5mg was introduced by Cipla Limited and its fully-owned subsidiary Cipla USA Inc. A New Drug Application (NDA) filed under the 505(b)(2) regulatory pathway served as the basis for the product’s approval by the US Food and Drug Administration (the “US FDA”).
- In March 2022, CAMCEVITM (leuprolide) 42mg injectable emulsion was launched in the United States for the treatment of advanced prostate cancer in adults, according to Accord BioPharma, the U.S. specialty branch of Intas Pharmaceuticals, Ltd.
Top Companies in the Leuprorelin Drugs Market
- Takeda Pharmaceutical
- Beijing Biote Pharmaceutical
- Accord BioPharma
- Sun Pharmaceutical
- AbbVie
- Cipla
- Tolmar
- Merck
- Eugia Pharma
- Foresee Pharmaceuticals
- Livzon Pharmaceuticals
Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/leuprorelin-drugs-market-sizing
To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5282
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.
Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare